BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 38091642)

  • 1. Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH).
    Auger N; Douet-Guilbert N; Quessada J; Theisen O; Lafage-Pochitaloff M; Troadec MB
    Curr Res Transl Med; 2023; 71(4):103409. PubMed ID: 38091642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytogenetic place in managing myelodysplastic syndromes: an update by the Groupe francophone de cytogénétique hématologique (GFCH).
    Eclache V; Lafage-Pochitaloff M; Lefebvre C; Penther D; Raynaud S; Tigaud I
    Ann Biol Clin (Paris); 2016 Oct; 74(5):525-534. PubMed ID: 27546835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q).
    Makishima H; Rataul M; Gondek LP; Huh J; Cook JR; Theil KS; Sekeres MA; Kuczkowski E; O'Keefe C; Maciejewski JP
    Leuk Res; 2010 Apr; 34(4):447-53. PubMed ID: 19758696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
    Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
    Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnosis and prognosis in myelodysplastic syndromes. The impact of cytogenetics].
    Mecucci C
    Recenti Prog Med; 2014 Mar; 105(3):110-4. PubMed ID: 24675452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome.
    Cordoba I; González-Porras JR; Nomdedeu B; Luño E; de Paz R; Such E; Tormo M; Vallespi T; Collado R; Xicoy B; Andreu R; Muñoz JA; Solé F; Cervera J; del Cañizo C;
    Cancer; 2012 Jan; 118(1):127-33. PubMed ID: 21717439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion.
    Feurstein S; Thomay K; Hofmann W; Buesche G; Kreipe H; Thol F; Heuser M; Ganser A; Schlegelberger B; Göhring G
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescence in situ hybridization analysis of 110 hematopoietic disorders with chromosome 5 abnormalities: do de novo and therapy-related myelodysplastic syndrome-acute myeloid leukemia actually differ?
    Lessard M; Hélias C; Struski S; Perrusson N; Uettwiller F; Mozziconacci MJ; Lafage-Pochitaloff M; Dastugue N; Terré C; Brizard F; Cornillet-Lefebvre P; Mugneret F; Barin C; Herry A; Luquet I; Desangles F; Michaux L; Verellen-Dumoulin C; Perrot C; Van den Akker J; Lespinasse J; Eclache V; Berger R;
    Cancer Genet Cytogenet; 2007 Jul; 176(1):1-21. PubMed ID: 17574959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.
    Solé F; Luño E; Sanzo C; Espinet B; Sanz GF; Cervera J; Calasanz MJ; Cigudosa JC; Millà F; Ribera JM; Bureo E; Marquez ML; Arranz E; Florensa L
    Haematologica; 2005 Sep; 90(9):1168-78. PubMed ID: 16154839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
    Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications.
    Bruzzese A; Martino EA; Mendicino F; Lucia E; Olivito V; Capodanno I; Neri A; Morabito F; Vigna E; Gentile M
    Eur J Haematol; 2024 Jun; 112(6):860-869. PubMed ID: 38294126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Copy Number Variations in the Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients with del(5q) and/or -7/del(7q).
    Zhang R; Kim YM; Wang X; Li Y; Lu X; Sternenberger AR; Li S; Lee JY
    Int J Med Sci; 2015; 12(9):719-26. PubMed ID: 26392809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cytogenetic abnormalities of 50 MDS patients by FISH detection and conventional karyotype analysis].
    Gao DG; Li BT; Zhou LN; Chen H; Zhang B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1190-4. PubMed ID: 24156432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
    Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
    Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytogenetic and Southern blot analysis to demonstrate clonality and to estimate prognosis in patients with myelodysplastic syndromes.
    Schmetzer HM; Poleck B; Duell T; Gerhartz HH; Mittermüller J
    Ann Hematol; 2000 Jan; 79(1):20-9. PubMed ID: 10663617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.
    Wall M
    Methods Mol Biol; 2017; 1541():209-222. PubMed ID: 27910026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan.
    Tasaka T; Tohyama K; Kishimoto M; Ohyashiki K; Mitani K; Hotta T; Kanamaru A; Okamoto S; Karasawa M; Kimura A; Tomonaga M; Uchiyama T; Ozawa K;
    Leukemia; 2008 Oct; 22(10):1874-81. PubMed ID: 18668133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype.
    Rigolin GM; Bigoni R; Milani R; Cavazzini F; Roberti MG; Bardi A; Agostini P; Della Porta M; Tieghi A; Piva N; Cuneo A; Castoldi G
    Leukemia; 2001 Dec; 15(12):1841-7. PubMed ID: 11753603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
    Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
    Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.